Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9526813 | 1.00 | L3MBTL1 (0.63) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL28126918 | 0.82 | L3MBTL1 (0.61) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL5505530 | 0.82 | L3MBTL1 (0.61) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL8111744 | 0.81 | CES2 (0.50) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL28245619 | 0.80 | SRC (0.52) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL7773819 | 0.80 | SRC (0.52) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL2927912 | 0.78 | L3MBTL1 (1.00) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL7202862 | 0.78 | L3MBTL1 (0.55) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL5609578 | 0.77 | EPHX1 (0.46) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL3237992 | 0.77 | TDP1 (0.43) | L3MBTL1TDP1LMNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| EP-0099746-A1 | C-23-modified derivatives of macrolide antibiotics | ELI LILLY AND COMPANY (US) | 1984-02-01 | — | — | EP | claimed |
| CN-112043724-A | Application of arsenic-containing compound | 常州高新技术产业开发区三维工业技术研究所有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-111278840-A | Pyrrolo [2, 3-B ] pyridine compounds and their use for treating cancer | 癌症研究科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-104105755-B | PVC composition with high impact strength | 巴斯夫欧洲公司 | 2017-01-18 | — | — | CN | disclosed |
| EP-1836248-A1 | ANTISTATICALLY FINISHED POLYMER COMPOSITIONS THE PRODUCTION THEREOF AND THEIR USE | Baerlocher GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006066834-A1 | ANTISTATICALLY FINISHED POLYMER COMPOSITIONS THE PRODUCTION THEREOF AND THEIR USE | BAERLOCHER GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
| WO-1993005011-A1 | NOVEL IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | L3MBTL1 1103/4885TDP1 4444/4885LMNA 3499/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | L3MBTL1 1103/4885TDP1 4444/4885LMNA 3499/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | L3MBTL1 4515/4885TDP1 4798/4885LMNA 1516/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | L3MBTL1 4515/4885TDP1 4798/4885LMNA 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.